Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000991816 | SCV001143587 | uncertain significance | not provided | 2019-04-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000991816 | SCV001816751 | uncertain significance | not provided | 2023-12-17 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Labcorp Genetics |
RCV000991816 | SCV002256248 | likely benign | not provided | 2025-01-01 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000991816 | SCV003831161 | uncertain significance | not provided | 2022-06-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004030131 | SCV004928465 | uncertain significance | Inborn genetic diseases | 2024-03-04 | criteria provided, single submitter | clinical testing | The c.4898G>A (p.G1633D) alteration is located in exon 65 (coding exon 65) of the COL11A2 gene. This alteration results from a G to A substitution at nucleotide position 4898, causing the glycine (G) at amino acid position 1633 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004749580 | SCV005353407 | uncertain significance | COL11A2-related disorder | 2024-03-07 | no assertion criteria provided | clinical testing | The COL11A2 c.4898G>A variant is predicted to result in the amino acid substitution p.Gly1633Asp. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.013% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |